ternational
stant
cisive
formative
[email protected]/ [email protected] ASIA EDITION
www.biopectrumasia.com
Australia & 360biolabs
ideal location for
COVID-19 clinical trials
In one of the first COVID-19 clinical vaccine trials, US-based clinical-stage
biotechnology company Novavax (NASDAQ: NVAX) has selected Australian
speciality laboratory 360biolabs, to conduct sample analysis for the clinical trial
of its SARS-CoV-2 recombinant spike protein nanoparticle vaccine, NVX-CoV2373.
Due to the nature and sensitivities of certain assays used in this clinical trial, a
specialist biosecurity facility is required. With its highly experienced scientists
working in state of the art Biosafety Level 2 (BSL-2) and 3 (BSL-3) laboratories,
360biolabs has the ideal resources and environment to conduct these crucial studies.
“We are thrilled that an organization with the reputation and capabilities of
360biolabs agreed to work with us in this critical clinical trial”, said Gregory Glenn,
Novavax President of Research and Development. “We are confident 360biolabs will
provide timely and appropriate data results”.
As Australia’s only ISO accredited, clinical services organisation, currently working
with SARS-CoV-2, 360biolabs have received global requests for antiviral testing
and clinical trial support. 360biolabs’ wealth of knowledge in the respiratory virus
antiviral discovery and clinical space, ensures the team will delivery high quality,
robust and reliable data.
The Phase 1 trial of NVX-CoV2373 is expected to begin in May with preliminary
immunogenicity and safety results in July.
With fast start-up processes, quality data recognised by global regulatory bodies
and 43.5% R&D tax incentive for eligible companies, Australia is known globally
as a destination for early phase clinical trials.
Contact 85 Commercial Road,
Angela Luttick Melbourne, Victoria,
[email protected] 3004, Australia
T +61 3 9282 2184 www.360biolabs.com
The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Taiwan’s success story in combating COVID-19
COVID-19 has unravelled the potency and the feebleness of most geographical region’s healthcare, technical, social and political structure. While countries are anticipating various dimensions to tackle coronavirus and combat the pandemic, Taiwan’s success in controlling COVID-19 has bolstered its global standing despite the close geographical proximity with China. The resilient island aggregated its forces to tackle the virus and circumstances rationally with well-established pandemic control strategies, bio medical assets, advanced IoT capabilities, impeccable healthcare system and a well organised political force. Taiwan apparently grappled the coronavirus incredibly well and is now keen to offer medical and technical assistance to other countries in this global crisis.
Discover the best professional documents and content resources in AnyFlip Document Base.
Search